Chantix Emerges As A Favorite Quit Smoking Medicine In Spite Of Its Safety Concerns
Date: 19 th November 2008
According to a new disclosure by Kalorama Information, the Pfizer manufactured anti-smoking medicine Chantix is still a demanding smoking cessation medicine in the market despite the safety concerns associated with it. Moreover, "Smoking Cessation: World Markets", a report published by Kalorama Information, states that the sale of quit smoking medicines has risen by almost 32.6% within the period 2006 to 2007, mostly on account of the FDA(Food and Drugs Administration) approval granted to the Pfizer manufactured anti-smoking medicine in 2006.
Melissa Elder, Kalorama Information analyst, reveals that Chantix is demanded in the pharmaceutical market to a significant degree due to the reason that strong and effective quit smoking treatments, including prescription smoking cessation medicines, are not sufficiently available in the market. She adds that in spite of being highly demanded by consumers, enough prescription medicines are not available in the market and as of date there is no sign of a new product approval before the year 2011.
Finally, it appears that on account of the absence of competitors and the lack of new approvals granted to quit smoking products, Pfizer's Chantix, is likely to emerge as the most favorite smoking cessation drug in spite of the reduction in its sales due to the safety concerns associated with the medication.
Source: Kalorama Information